Kronos Bio, Inc. announced that its Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign from his position to pursue a new professional opportunity as the chief executive officer of a private biotechnology company. The Company has initiated a search to identify a suitable replacement for Dr. Al-Wakeel, who will remain with Kronos Bio until September 15, 2023 to ensure business continuity.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.995 USD | -2.45% | -5.24% | -20.40% |
09/05 | Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $2.52M | MT |
09/05 | Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.40% | 61.3M | |
+29.49% | 48.16B | |
-1.00% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.16% | 25.59B | |
-22.92% | 18.96B | |
+8.43% | 12.92B | |
+29.14% | 12.03B | |
-1.81% | 11.77B |
- Stock Market
- Equities
- KRON Stock
- News Kronos Bio, Inc.
- Kronos Bio Announces Resignation of Yasir Al-Wakeel as Head of Corporate Development, Effective from September 15, 2023